FDA Approves TAPENTADOL HYDROCHLORIDE — Novadoz Pharmaceuticals LLC
Novadoz Pharmaceuticals LLC recently received approval from the FDA for its Abbreviated New Drug Application (ANDA) filing for tapentadol hydrochloride, enhancing its portfolio fol…
SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.
Novadoz Pharmaceuticals LLC recently received approval from the FDA for its Abbreviated New Drug Application (ANDA) filing for tapentadol hydrochloride, enhancing its portfolio fol…
HANDA ONCOL announced Wednesday that the FDA approved its investigational therapy for the selected indication on September 3, 2026, which is anticipated to intensify competitive pr…
IONIS Pharmaceuticals announced an approval for its candidate, marking a significant milestone as the first product in its new therapeutic platform to demonstrate clinical efficacy…
On September 2, 2026, Precision Dose Inc. won FDA approval for ANDA214523, laying the groundwork for market expansion and revenue generation for the company's portfolio. The approv…
MSN announced the approval of a new generic drug, signaling a significant opportunity to capture market share within the pharmaceuticals sector. Furthermore, the authorization is e…
Dr. Reddy’s Laboratories Inc. has received FDA approval for its ANDA213234, granting market exclusivity to its oral generic version of pomalidomide starting August 31, 2026. This r…
Cipla USA Inc. received FDA approval Monday for Pomalidomide (ANDA219718), introducing an affordable oral alternative to the brand name drug for patients with multiple myeloma. Thi…
FDA Approves Stelara for Pediatric Ulcerative Colitis
FDA has granted full approval to Takeda Pharmaceuticals U.S.A., Inc. for a new drug application, a milestone that will significantly bolster the company’s commercial portfolio and …
Millennium Pharmaceuticals received significant market validation following the FDA's approval of its generic drug on August 28, 2026, which is anticipated to bolster its revenue s…
ORBICULAR PHARM TECH has received regulatory approval from the U.S. Food and Drug Administration for ANDA220938, bringing a novel substance to the market. This clearance is anticip…
Gilead Sciences received FDA approval for its newly submitted NDA on August 27, 2026, marking a significant strategic addition to its therapeutic portfolio. This regulatory milesto…
Gilead Sciences has secured FDA approval for Bixlenvo (bictegravir/lenacapavir), a new oral formulation of the long-acting combination therapy, which is expected to solidify the co…
SUN PHARMACEUTICAL INDUSTRIES LIMITED announced the United States FDA approval of its latest medication on August 26, marking a strategic entry into the U.S. market that is expecte…
Revolution Medicines today achieved a significant strategic milestone with the FDA approval of NDA220910 for DARAXONRASIB (oral), a development that broadens the company's portfoli…
Zydus Lifesciences received FDA approval for its ANDA submission, setting the stage for commercialization and the potential to capture market share in the relevant therapeutic spac…
Laurus Labs Limited received FDA approval on August 20, 2026, for the anticoagulant Ticagrelor, marking a significant milestone in the company's expansion of its late-stage pipelin…
Glenmark Pharmaceuticals Inc. has received a final FDA approval for the ANDA for Fluticasone Propionate Nasal Spray, which is set to expand its portfolio in a market currently driv…
STERINIVA INC received regulatory approval from the FDA on August 18, 2026, but the document does not specify the product name or substance, making it impossible to assess the fina…
Jubilant Generics announced the FDA approval on August 17, 2026, for its abbreviated new drug application ANDA210592, marking a strategic expansion of its U.S. portfolio and positi…